Lambda Therapeutic Research

Executive Summary

Lambda Therapeutic Research is a global full-service Contract Research Organization (CRO) headquartered in Ahmedabad, India, providing end-to-end clinical development services from early-phase to post-marketing studies. Founded in 2020, the company has rapidly grown to employ 500-1,000 professionals and specializes in biosimilar development across 15+ therapeutic areas, with deep expertise in oncology, hematology, and immunology. Lambda offers a comprehensive suite of services including clinical trial management, regulatory affairs, pharmacovigilance, and analytical laboratory services, positioning itself as a one-stop partner for pharmaceutical and biotech clients. The CRO market in India is expanding, driven by cost advantages and a large patient pool. Lambda's focus on biosimilars is particularly timely as patents on many biologics expire, creating demand for affordable alternatives. While the company is private and does not disclose financials, its rapid growth and broad service offering suggest a strong competitive position. However, the CRO industry faces challenges including regulatory scrutiny and talent retention. Looking ahead, Lambda's ability to secure large contracts and expand its global footprint will be key to sustaining momentum. The company's conviction score is 75, reflecting steady growth prospects but limited visibility due to private status.

Upcoming Catalysts (preview)

• Q4 2026Major biosimilar development contract with top pharmaceutical company60% success
• Q2 2027Expansion of laboratory facilities or acquisition of a specialized CRO50% success
• Q1 2027Regulatory approval or milestone achievement in a biosimilar program managed by Lambda40% success